Compare BTOC & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTOC | CVKD |
|---|---|---|
| Founded | 2020 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 13.8M |
| IPO Year | 2023 | 2022 |
| Metric | BTOC | CVKD |
|---|---|---|
| Price | $0.29 | $5.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 226.6K | 43.8K |
| Earning Date | 05-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $190,408,258.00 | N/A |
| Revenue This Year | $34.89 | N/A |
| Revenue Next Year | $14.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.03 | N/A |
| 52 Week Low | $0.23 | $4.21 |
| 52 Week High | $1.78 | $17.00 |
| Indicator | BTOC | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 50.88 |
| Support Level | $0.27 | $5.13 |
| Resistance Level | $0.34 | $6.09 |
| Average True Range (ATR) | 0.02 | 0.54 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 48.76 | 67.72 |
Armlogi Holding Corp is a fast-growing U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions relating to warehouse management and order fulfillment. The company provides one-stop warehousing and logistics services to cross-border e-commerce merchants outside the U.S. who seek to sell in the U.S. market. The warehouses are equipped with automated sorting systems, heavy-duty forklifts, and pallets and trays that are suitable for processing bulky items. The services of the company include customs brokerage services, transportation of merchandise to U.S. warehouses, and warehouse management and order fulfillment services.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.